Exploring the effect of combining radiotherapy and metformin

Radiotherapy and Metformin on Radiosensitivity Enhancement in Patients with Rectal Cancer Considering All Prior Exposures to Ionizing and Non-Ionizing Radiation Before Treatment Initiation.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251226068447N1

Enrollment

Registered

2026-01-27

Start date

2026-02-04

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer. Malignant neoplasm of rectum

Interventions

Intervention 1: Intervention group: Radiotherapy with metformin: (Take 3 metformin tablets (dose 500 mg per day). Radiotherapy will be performed at 5 Gy per session, 5 days a week. For 5 sessions and

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients referred to the radiotherapy department of Namazi Hospital and the oncology clinic of Motahari Clinic Definitive diagnosis of colorectal cancer in the rectal area with appendages and staging T=3 or lymph node involvement Age 18 to 70 years

Exclusion criteria

Exclusion criteria: History of metformin use Having metabolic diseases Acute cardiovascular diseases Diabetes Liver and kidney diseases Acidosis and pregnancy

Design outcomes

Primary

Measure	Time frame
Increase in radio-sensitivity. Timepoint: The effect of using metformin in radiotherapy will be measured at the end of treatment. Method of measurement: The variable is measured by measuring biomarkers and tumor size before and after treatment.;Reduce in tumor size. Timepoint: The effect of using metformin in radiotherapy will be measured at the end of treatment. Method of measurement: The variable is measured by measuring biomarkers and tumor size before and after treatment.	—

Measure

Time frame

Increase in radio-sensitivity. Timepoint: The effect of using metformin in radiotherapy will be measured at the end of treatment. Method of measurement: The variable is measured by measuring biomarkers and tumor size before and after treatment.;Reduce in tumor size. Timepoint: The effect of using metformin in radiotherapy will be measured at the end of treatment. Method of measurement: The variable is measured by measuring biomarkers and tumor size before and after treatment.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmirali Fallah

Shiraz University of Medical Sciences

amiralifallah978@gmail.com+98 28 3336 6363

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026